CureVac stops development of its COVID-19 shot, will focus on new COVID-19 vaccine set for 2022
Marketwatch -

Shares of CureVac tumbled 9.6% in premarket trading on Tuesday after the German biopharmaceutical company said it will scrap development of its COVID-19 vaccine candidate and instead focus on developing second-generation mRNA shots against COVID-19 with GlaxoSmithKline . The existing purchase agreement with the European Commission is no longer in place. They are aiming to bring a new COVID-19 vaccine to market in 2022. "The decision is also aligned with the evolving dynamics of the pandemic...

Read this story at

Loading...

Related Articles